Loading...
XSHE
002332
Market cap1.29bUSD
Dec 05, Last price  
9.22CNY
1D
0.33%
1Q
-12.94%
Jan 2017
7.46%
IPO
12.58%
Name

Zhejiang Xianju Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002332 chart
P/E
22.96
P/S
2.28
EPS
0.40
Div Yield, %
3.25%
Shrs. gr., 5y
1.62%
Rev. gr., 5y
1.53%
Revenues
4.00b
-2.98%
765,330,681966,789,3371,133,516,5221,276,721,0341,500,980,9331,689,209,5981,992,191,5442,315,040,5652,470,533,0192,480,246,1532,503,730,3452,852,555,2623,621,754,7133,708,545,5304,018,872,7724,337,150,9644,379,825,6954,123,418,5844,000,693,148
Net income
397m
-29.46%
49,529,72464,636,46165,037,69988,841,792120,165,635132,869,614120,557,25460,591,46856,695,716106,551,038146,186,888206,630,126301,362,969410,368,585504,509,427619,325,646749,411,381563,083,493397,178,995
CFO
399m
-33.05%
53,052,17996,534,59036,030,822104,678,023155,292,369147,627,79833,427,87163,461,725141,638,736199,607,086155,905,554167,466,085193,266,995519,805,113789,233,376676,151,765609,284,602595,482,358398,655,375
Dividend
Jun 05, 20240.3 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Xianju Pharmaceutical Co.,Ltd. manufactures and sells steroids and hormones worldwide. The company offers active pharmaceutical ingredients, such as steroid drugs, and male and female hormones; intermediates; and finished formulations in the form of tablets, capsules, granules, soft capsules, powder inhalations, creams, gels, injections, and powder-injections. Zhejiang Xianju Pharmaceutical Co.,Ltd. was founded in 1972 and is based in Xianju, China.
IPO date
Jan 12, 2010
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT